Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
KARD · against 453 other Healthcare companies of similar size
Ranked #420 of 454 · scores higher than 0% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 0–9, including KARD · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | KARD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 444 reported | -21.6% | 1.5% | 6% | 30% | |
| EBITDA yieldHigher is better · 459 reported | -35.2% | 4.5% | 3% | 50% | |
| Free cash flow yieldHigher is better · 204 reported | Not reported | -1.1% | — | — | 20% |
| Book yieldHigher is better · 449 reported | 46.0% | 40.4% | 57% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 1 | 14.8B MXN (≈$800M) | 99 | 61 | |
| 420 | 1.8B USD | 0 | 30 | |
| 420 | 1.2B CHF (≈$1.3B) | 0 | 28 | |
| 420 | 952M USD | 0 | 3 | |
| 420 | 1.4B USD | 0 | ||
| 420 | 1.3B USD | 0 | ||
| 420 | 1.6B USD | 0 | ||
| 420 | 1.0B EUR (≈$1.1B) | 0 | 16 | |
| 420 | 1.0B USD | 0 | 32 | |
| 420 | 1.8B AUD (≈$1.2B) | 0 | 41 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score